Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Vaia Vlamis"'
Autor:
Madhu Mazumdar, Paul M. Dodd, Dean F. Bajorin, John A. McCaffrey, Harry Herr, B S Geralyn Higgins, Howard Scher, B S Vaia Vlamis
Publikováno v:
Cancer. 85:1145-1150
BACKGROUND This study was undertaken to determine whether the use of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin as first-line therapy increases the proportion of major responders and overall survival in
Autor:
George Holcomb, Michael P. La Quaglia, Richard G. Azizkhan, Charles A. Sklar, Thomas J. Black, Kurt D. Newman, Gerald M. Haase, Glenn Heller, Vaia Vlamis
Publikováno v:
Annals of Surgery. 227:533-541
OBJECTIVE: This study was done to define the extent of disease and evaluate the effect of staging and treatment variables on progression-free survival in patients with differentiated thyroid carcinoma who were less than 21 years of age at diagnosis.
Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin
Autor:
J Spicer, George J. Bosl, Vaia Vlamis, M F Sarosdy, Dean F. Bajorin, M Mazumdar, Robert J. Motzer, Hong Xiao, Joseph Ferrara
Publikováno v:
Journal of Clinical Oncology. 15:2553-2558
PURPOSE To assess the durability of response and overall survival for patients with good-risk metastatic germ cell tumors (GCT) treated with four cycles of etoposide and cisplatin (EP). PATIENTS AND METHODS Two hundred fourteen patients treated with
Autor:
M Mazumdar, Vaia Vlamis, George J. Bosl, Robert J. Motzer, John A. McCaffrey, Dean F. Bajorin
Publikováno v:
Journal of Clinical Oncology. 15:2559-2563
PURPOSE To evaluate the efficacy and toxicity of ifosfamide- and cisplatin-containing chemotherapy as first-line salvage treatment for patients with germ cell tumors (GCT). PATIENTS AND METHODS Fifty-six patients with advanced GCT resistant to one pr
Autor:
Ann M. Dnistrian, Tracy Curley, Madhu Mazumdar, C. Leibertz, David G. Pfister, Wm. Kevin Kelly, Howard I. Scher, Vaia Vlamis, Morton K. Schwartz, Lee Ann Cohen
Publikováno v:
Journal of Clinical Oncology. 13:2214-2222
PURPOSE The combination of suramin and hydrocortisone has shown clinical benefit in patients with androgen-independent prostate cancer. Widespread use was limited by the complex dose schedules and the need for pharmacologic monitoring. This study rep
Autor:
Kenneth W. Sell, Michael O'Connell, Madhu Mazumdar, Dean F. Bajorin, Vaia Vlamis, Philip J. Walther, Robert J. Motzer, Teresa Murray Law, Amanullah Khan M.D., N. J. Vogelzang
Publikováno v:
Cancer. 76:824-832
Background. Treatment with interleukin-2 (IL-2) and lymphokine-activated killer cells (LAK) resulted in responses in some patients with advanced renal cell carcinoma (RCC). However, the relative therapeutic benefit of the addition of LAK to IL-2 was
Autor:
Lawrence H. Schwartz, A D Hoffman, Robert J. Motzer, Anthony P. Albino, T M Law, Vaia Vlamis, Barbara A. Murphy, David M. Nanus
Publikováno v:
Journal of Clinical Oncology. 13:1950-1957
PURPOSE A phase II trial of interferon alfa-2a (IFN) and 13-cis-retinoic acid (CRA) was conducted in patients with renal cell carcinoma (RCC). In vitro studies were performed to investigate potential mechanisms of interaction. PATIENTS AND METHODS Fo
Autor:
George Y. Wong, Stephen C. Rubin, William J. Hoskins, Walter B. Jones, Luis Vaccarello, Vaia Vlamis, John L. Lewis
Publikováno v:
Gynecologic Oncology. 57:61-65
Recurrent ovarian cancer after negative findings at second-look laparotomy is common. A retrospective review of 57 patients who developed recurrent tumor after a negative second-look laparotomy was undertaken to evaluate treatment efficacy and progno
Autor:
R N Jean McCarthy Lepore, George Y. Wong, Kathleen M. Foley, Alice B. Kornblith, B R N Diane Loseth, Thomas Hakes, Russell K. Portenoy, William J. Hoskins, Vaia Vlamis
Publikováno v:
Cancer. 74:907-915
Background. The prevalence, characteristics, and impact of pain and other symptoms have not been studied systematically in women with ovarian cancer. Anecdotally, pain has been associated with the onset of the disease and is a common problem among th
Autor:
Barbara A. Murphy, Dean Bajorin, George J. Bosl, Jerome S. Nisselbaum, Vaia Vlamis, Robert J. Motzer, Madhu Mazumdar
Publikováno v:
Cancer. 73:2520-2526
Background. Serum tumor marker regression (alpha-fetoprotein [AFP] and human chorionic gonadotrophin [hCG]) was studied in patients treated with ifosfamide-based chemotherapy for cisplatin-resistant germ cell tumors (GCT) to investigate the role of m